Immunomodulatory drugs in the treatment of myelodysplastic syndromes

Current Opinion in Oncology

Volumn 19, Issue 6, 2007, Pages 656-659

  Ortega, Jose ^a   List, Alan ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Deletion 5q; IMiDs; Lenalidomide; MDS; Myelodysplastic syndrome

Indexed keywords

IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE;

ANGIOGENESIS; APOPTOSIS; CHROMOSOME DELETION 5; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; ERYTHROPOIESIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LYMPHOCYTE ACTIVATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CLINICAL TRIALS AS TOPIC; HUMANS; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34848819101     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f0e12b     Document Type: Review

References (27)

1. List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol 2005; 32 (4 Suppl 5):S31-S35.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of myeloid neoplasms. Blood 2002; 100:2292-2302.
3. Greenberg PL. Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res 1998; 22 (Suppl 1):S3-S6.
4. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
5. List AF. Advances in the treatment of myelodysplastic syndromes: the emergence of immunomodulatory drugs. Haematologica 2006; 91 (Suppl 1):167-170. This article is an excellent review of the biological effects of the IMiDs, as well as the clinical evidence supporting their use in MDS. The author helped develop lenalidomide as an effective treatment for MDS.
6. Kale V, List AF. Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. Curr Pharm Biotechnol 2006; 7:339-342. This is a comprehensive review of the biology and clinical trial data on IMiDs in the treatment of MDS.
7. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58 (Suppl 1):I107-I113.
8. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31:213-221.
9. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96:3671-3674.
10. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98:958-965.
11. Muller GW, Chen R, Huang S-Y, et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production. Bioorg Med Chem Lett 1999; 9:1625-1630.
12. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4:314-344.
13. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-386.
14. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007; 109:4816-4824. This paper describes reduced NK cytotoxicity in high risk MDS. IMiDs augment NK cell activity.
15. Musto P. Thalidomide therapy for myelodysplastic syndromes: Current status and future perspectives. Leuk Res 2004; 28:325-332.
16. List AF, Estes M, Williams A, et al. Lenalidomide (CC-5013; Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition [abstract]. Blood 2006; 108:397a.
17. Dredge K, Marriott J, Macdonald C, et al. Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87:1166-1172.
18. List A, Tate W, Glinsmann-Gibson B. The immunomodulatory thalidomide analog, CC5013, inhibits trophic response in VEGF in AML cells by abolishing cytokine-induced P13/Akt activation. Blood 2002; 100:139.
19. Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55:77-92.
20. Gandhi AK, Naziruddin S, Verhelle D, et al. Antiproliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic lymphoma (ALL) cell lines [abstract]. J Clin Oncol 2004; 22 (Suppl 14S):587s.
21. List A, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndrome. Cancer Control 2006; 13 (Suppl.):4-11. This paper describes the increased marrow apoptotic index resulting from lenalidomide therapy in MDS patients with deletion 5q and reduction in the marrow proliferative index in nondeletion 5q responders.
22. List A, Kurtin S, Roe D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:11-19.
23. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:38-47. This landmark study evaluated lenalidomide treatment for MDS patients with deletion 5q. High rates of transfusion independence and durable responses are described.
24. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005; 19:1424-1431.
25. List AF, Dewald G, Bennett J, et al. Results of the MDS-002 and -003 international phase II studies evaluating lenalidomide (CC-5013, Revlimid®) in the treatment of transfusion-dependent patients with myelodysplastic syndrome (MDS). Haematologica 2005; 90 (Suppl 2):307a.
26. Celgene Corp. Revlimid package insert. Summit: Celgene Corp; 2006.
27. Kurtin S, Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control 2006; 13 (Suppl):26-31. This article describes the clinical implications of the data regarding lenalidomide therapy for lower risk MDS.